

## Clinical and Biological Significance of *CDK4* Amplification in Well-Differentiated and Dedifferentiated Liposarcomas

Antoine Italiano,<sup>1,3</sup> Laurence Bianchini,<sup>1,3</sup> Elisabet Gjernes,<sup>1,3</sup> Frédérique Keslair,<sup>1</sup> Dominique Ranchere-Vince,<sup>5</sup> Jean-Marc Dumollard,<sup>6</sup> Juliette Haudebourg,<sup>2</sup> Agnès Leroux,<sup>7</sup> Claire Mainguéné,<sup>8</sup> Philippe Terrier,<sup>9</sup> Frédéric Chibon,<sup>4</sup> Jean-Michel Coindre,<sup>4</sup> and Florence Pedeutour<sup>1,3</sup>

**Abstract Purpose:** The *MDM2* and *HMGA2* genes are consistently amplified in well-differentiated/dedifferentiated liposarcomas (WDLPS/DDLPS) whereas *CDK4* is frequently but not always amplified in these tumors. Our goal was to determine whether the absence of *CDK4* amplification was (a) correlated to a specific clinico-histopathologic profile; and (b) compensated by another genomic anomaly involving the *CCND1/CDK4/P16INK4a/RB1/E2F* pathway.

**Experimental Design:** We compared the clinical characteristics of a series of 143 WDLPS/DDLPS with amplification of both *MDM2* and *CDK4* (*MDM2+/CDK4+*) to a series of 45 WDLPS/DDLPS with *MDM2* amplification and no *CDK4* amplification (*MDM2+/CDK4-*). We used fluorescence *in situ* hybridization, real time quantitative reverse transcription PCR, and immunohistochemistry to explore the status of *CCND1*, *P16INK4a*, *P14ARF*, and *RB1*.

**Results:** We found that *MDM2+/CDK4-* WDLPS/DDLPS represent a distinct clinical subgroup with favorable prognostic features, including low-grade lipoma-like histology, peripheral location, and lower rate of recurrence. By using fluorescence *in situ* hybridization, we found that genomic aberrations expected to be alternative mechanisms for compensating the lack of *CDK4* amplification, such as *RB1* and *CDKN2A* deletions or *CCND1* amplification, were very uncommon. In contrast, by using real time quantitative reverse transcription PCR and immunohistochemistry, we observed that overexpression of *P16INK4a* (and *P14ARF*) and *CCND1* and reduced expression of *RB1* were very frequent, independently of the *CDK4* status.

**Conclusions:** Our results underscore the complex coordinated regulation of the RB and p53 growth-control pathways in WDLPS/DDLPS. Because the absence of *CDK4* amplification is not specifically counterbalanced by a genomic alteration of the *CCND1/CDK4/P16INK4a/RB1/E2F* pathway, *CDK4* amplification may only represent a "MDM2-HMGA2-helper" in WDLPS/DDLPS tumorigenesis. (Clin Cancer Res 2009;15(18):5696-703)

The *CDK4* gene encodes a 33-kD protein that plays an important role in the regulation of the G<sub>1</sub>-S transition of the cell cycle (1). *CDK4* forms molecular complexes with members of the cyclin D family, such as cyclin D1 (*CCND1*). The phosphorylation of RB1 protein by the *CDK4-CCND1* complex leads to the release of the E2F transcription factor, which up-regulates gene expression required for progression through the S-, G<sub>2</sub>-, and M-phases (1). The activity of *CDK4* is negatively regulated

by p16INK4a, which prevents its binding to *CCND1* (Fig. 1). p16INK4a is the product of the *CDKN2A* gene that also encodes p14ARF (2). Alterations of genes involved in the *CCND1/CDK4/p16INK4a/RB1/E2F* pathway play a crucial role in the pathogenesis of many tumor types (1, 3).

We and others have shown that well-differentiated/dedifferentiated liposarcoma (WDLPS/DDLPS) cells contain supernumerary ring or giant marker chromosomes composed of highly

**Authors' Affiliations:** <sup>1</sup>Laboratory of Solid Tumors Genetics and <sup>2</sup>Department of Pathology, Nice University Hospital, and <sup>3</sup>CNRS, UMR 6543, Faculty of Medicine, University of Nice Sophia-Antipolis, Nice, France; <sup>4</sup>Department of Pathology, Institut Bergonié, Bordeaux, France; <sup>5</sup>Department of Pathology, Centre Léon Bérard, Lyon, France; <sup>6</sup>Department of Pathology, Saint-Etienne University Hospital, Saint-Etienne, France; <sup>7</sup>Department of Pathology, Centre Alexis Vautrin, Nancy, France; <sup>8</sup>Department of Pathology, Princess Grace Hospital, Monaco; and <sup>9</sup>Department of Pathology, Institut Gustave Roussy, Villejuif, France  
Received 12/8/08; revised 5/12/09; accepted 6/15/09; published OnlineFirst 9/8/09.

**Grant support:** Programme Hospitalier de Recherche Clinique (PHRC Na-

tional 2003; Nice University Hospital), Comité des Alpes-Maritimes de la Ligue Nationale Contre le Cancer, Conseil Général des Alpes-Maritimes, Association pour la Recherche sur le Cancer (ARC# 4080 to FP), and Institut National du Cancer (projet libre GENOSTT).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

**Requests for reprints:** Antoine Italiano, Institut Bergonie, Department of Medical Oncology, 229 cours de l'Argonne, 33000 Bordeaux, France. Phone: 336-813-88799; Fax: 335-563-33353; E-mail: italiano@bergonie.org.

© 2009 American Association for Cancer Research.

doi:10.1158/1078-0432.CCR-08-3185

### Translational Relevance

Well-differentiated/dedifferentiated liposarcoma (WDLPS/DDLPS) is the most frequent sarcoma subtype in adult patients. WDLPS/DDLPS are characterized by a consistent amplification of the 12q14-15 chromosomal region containing the *MDM2* and *HMGA2* genes in all the cases, whereas the *CDK4* gene is only inconsistently amplified. *CDK4* and other cyclin-dependent kinases play a crucial role in the control of the cell cycle progression and are the target of several anticancer drugs in clinical development. We report here the first study investigating the clinical significance of *CDK4* amplification in WDLPS/DDLPS and the genomic aberrations involving the *CCND1/CDK4/P16INK4a/RB1/E2F* pathway in this tumor type.

amplified sequences from the 12q14-15 chromosomal region (4, 5). Although the *MDM2* and *CDK4* genes were initially considered to be the two main targets of the 12q14-15 amplicon in WDLPS/DDLPS, we have recently shown (6) that only *MDM2* (12q15) and *HMGA2* (12q14.3) were consistently amplified in WDLPS/DDLPS. The *CDK4* gene (12q14.1) belongs to a distinct inconsistent amplicon that is not present in about 10% of cases (6). The concomitant amplification of *MDM2* and *HMGA2* seems therefore to be the crucial event in WDLPS/DDLPS pathogenesis. However, considering the important function of *CDK4*


in the cell cycle, *CDK4* gene amplification and overexpression very likely play an important role in the tumorigenic process. This may have clinical implications because several anticancer drugs belonging to the group of "CDK inhibitors" are currently in preclinical development or under clinical trials (7).

Further clarification of the role of *CDK4* amplification in WDLPS/DDLPS is needed for a better understanding of the tumorigenesis of such tumors. We report here a study which aimed at determining whether the absence of *CDK4* amplification in WDLPS/DDLPS is (a) correlated with specific clinicopathologic features, and (b) compensated by another genomic event involved in the *CCND1/CDK4/p16INK4a/RB1/E2F* pathway.

### Patients and Methods

**Patients.** From 1991 to 2008, 45 cases of WDLPS/DDLPS, for which amplification of *MDM2* but no amplification of *CDK4* was detected (*MDM2*+/*CDK4*-), were retrieved from the respective databases of the Laboratory of Solid Tumor Genetics (Nice, France) and of the Department of Pathology of the Bergonié Institute (Bordeaux, France). The clinicopathologic characteristics of these cases were compared with those of a series of 143 WDLPS/DDLPS with amplification of both *MDM2* and *CDK4* (*MDM2*+/*CDK4*+) analyzed during the same period. In all the cases, the diagnosis of WDLPS/DDLPS was established according to the WHO Classification of Tumors (4). The *MDM2/CDK4* status of all the cases was assessed by fluorescence *in situ* hybridization (FISH) and/or quantitative PCR as previously described (8).

**Molecular cytogenetic analysis.** FISH analysis was done in 30 cases (18 *MDM2*+/*CDK4*-, 12 *MDM2*+/*CDK4*+) with available formalin-fixed, paraffin-embedded blocks, in order to determine the genomic



**Fig. 1.** Schematic involvement of the *CCND1/CDK4/P16INK4a/RB1/E2F* pathway in the G<sub>1</sub>-S transition of the cell cycle. Accumulation of the *CCND1-CDK4* complex leads to phosphorylation of the retinoblastoma protein (RB1), allowing E2F to promote expression of genes that leads to the progression from the G<sub>1</sub> phase to the S phase of the cell cycle. The activity of the *CCND1-CDK4* complex is negatively regulated by P16INK4a that inhibits CDK4.

status of the *CDKN2A* (9p21.3), *CCND1* (11q13.3), and *RB1* (13q14.2) genes. Five-micrometer sections were deparaffinized, rehydrated, and incubated with pepsin by using the Histology FISH Accessory Kit (Dako) according to the manufacturer's instructions. Three FISH probes were used in this study: the p16/CEP9 Dual Color Probe (Abbott Molecular), and the bacterial artificial chromosome probes RP11-156B3 (11q13.3, *CCND1*) and RP11-839E5 (13q14.2, *RB1*). BAC clones from the Roswell Park Cancer Institute library were selected according to their location on the University of California Santa Cruz database (<http://genome.ucsc.edu/>; March 2006 release), were obtained from the Children's Hospital Oakland Research Institute (CHORI) (<http://bacpac.chori.org/>), and were prepared as probes for FISH analysis according to standard procedures. Microscopic analysis was done using a DM6000B microscope (Leica) and images were processed using the ISIS software (MetaSystems). At least 100 nuclei per slide were analyzed. Amplification was defined as the presence of  $\geq 10$  fluorescent signals per cell in  $>1\%$  of cells. Deletion was defined as  $>50\%$  nuclei with only one fluorescent signal.

**Array comparative genomic hybridization analysis.** DNA from frozen material of three cases of *MDM2+/CDK4-WDLPS/DDLPS* was extracted and processed for array comparative genomic hybridization (array-CGH) as previously described (9). The microarray used contained 3,342 sequence-validated BAC with an average resolution of 1 Mb (9).

**Quantitative reverse transcription-PCR analysis.** Quantitative reverse transcription-PCR (qRT-PCR) was used to determine the expression levels of *p16INK4a*, *p14ARF*, *CCND1*, and *RB1* in 16 *WDLPS/DDLPS* cases (7 *MDM2+/CDK4-*, 9 *MDM2+/CDK4+*) for which frozen material was available and in the 4 *MDM2+/CDK4+* *WDLPS/DDLPS* cell lines 93449, 94778, 95T1000, and 98T1430 (6). Total RNAs were extracted from *WDLPS/DDLPS* and normal subcutaneous adipose tissue (NSAT) using either the RNeasy lipid tissue minikit (Qiagen; frozen fragments) or Trizol (Invitrogen; *WDLPS/DDLPS* cell lines) according to the manufacturer's protocol. The RNA samples were treated by DNA-free (Applied Biosystems). One microgram of total RNA was reverse-transcribed into cDNA using the High Capacity cDNA Reverse Transcription kit (Applied Biosystems) and each qRT-PCR experiment was done twice in duplicate with the ABI PRISM 7300 Detection System using either FAM dyes (Applied Biosystems) for *CCND1*, *RB1*, and *p14ARF* or SYBRGreen dye for *p16INK4a* according to the manufacturer's protocol. *RPLP0* (the large P0 subunit of the acidic ribosomal phosphoprotein) was used as endogenous control for normalization. QRT-PCR was done using the following TaqMan gene expression assays (Applied Biosystems): Hs99999189\_m1 (*p14ARF*), Hs 00277039\_m1 (*CCND1*), Hs 01078066\_m1 (*RB1*), and Hs99999902\_m1 (*RPLP0*). The reaction mix consisted of 10  $\mu$ L of TaqMan master mix 2X, 1  $\mu$ L of TaqMan gene expression mix, and 5  $\mu$ L of 1/10 cDNA in a final volume of 20  $\mu$ L. For SYBRGreen experiments, primer sequences were the following: *RPLP0* forward: TGCATCAGTACCC-CATTCTATCAT, *RPLP0* reverse: AAGGTGTAATCCGTCTCCACAGA, *p16INK4a* forward: GGGGGCACCAGAGGCAGT, and *p16INK4a* reverse: GGTTGTGGCGGGGCGAGT. The reaction mix consisted of 12.5  $\mu$ L of SYBR Green PCR Master Mix (Applied Biosystems), 300 nmol/L forward and reverse primers and 5  $\mu$ L of 1/10 cDNA in a final volume of 25  $\mu$ L. Amplification of specific transcripts was confirmed by melting curve profiles generated at the end of the PCR program.

The PCR conditions were 2 min at 50°C and 10 min at 95°C, followed by 40 cycles at 95°C for 15 s and 60°C for 1 min. The comparative Ct (threshold cycle) method was used to achieve relative quantification of gene expression. The mRNA levels of genes of interest (R) were normalized to the mRNA levels of *RPLP0*:  $\Delta Ct = Ct_R - Ct_{RPLP0}$ . The relative amount of mRNA between controls (NSAT) and *WDLPS/DDLPS* was given by  $2^{-\Delta\Delta Ct}$  where  $\Delta\Delta Ct = \Delta Ct_R$  of *WDLPS/DDLPS* - mean of  $\Delta Ct_R$  of controls (NSAT). The  $\Delta Ct$  values of the controls were homogenous.

**Immunohistochemistry.** Immunohistochemical staining was done on representative slides from each case, following the manufacturer's instructions with the following primary antibodies: CDK4 (clone DCS-31, Biosource International), P16 (CINtech P16-INK4A kit, clone E6H4, Dako North America, Inc.), and CYCLIND1 (clone SP4, Neomarkers). Appropriate positive and negative controls were used.

**Statistical analysis.** Descriptive statistics were used to show the distribution of variables in the population. Differences between groups were evaluated by  $\chi^2$  test or Fisher's exact test for categorical variables and *t* test for continuous variables.


## Results

***MDM2+/CDK4- WDLPS/DDLPS are more frequently low-grade lipoma-like lesions occurring in the limbs and have more favorable outcome than MDM2+/CDK4+ WDLPS/DDLPS.*** The clinicopathologic characteristics of the patients are described in Table 1. In comparison with *MDM2+/CDK4+ WDLPS/DDLPS*, *MDM2+/CDK4- WDLPS/DDLPS* were more frequently low-grade lipoma-like lesions (64% versus 40%;  $P = 0.0039$ ) and occurred in the majority of cases in the deep soft tissues of the extremities (71% versus 47%;  $P = 0.0045$ ). They were very rarely located in the retroperitoneum (7%), whereas the *MDM2+/CDK4+* tumors were retroperitoneal lesions in 35% of cases ( $P = 0.0002$ ). Follow-up data were available for 56 patients with primary lesions at diagnosis (32 *MDM2+/CDK4+*, 24 *MDM2+/CDK4-*). The mean follow-up was 61 months for *MDM2+/CDK4+* and 46 months *MDM2+/CDK4-* patients. The local recurrence rate was significantly higher in patients with *MDM2+/CDK4+* tumors than in patients with *MDM2+/CDK4-* tumors (47% versus 12.5%;  $P = 0.0064$ ). The distant recurrence rate was not statistically different between the two groups (12.5% versus 9.5%;  $P = 0.71$ ). Ten deaths related to the disease were

**Table 1.** Patient characteristics (N = 188)

	<b>MDM2+/CDK4+ (%) (n = 143)</b>	<b>MDM2+/CDK4- (%) (n = 45)</b>
Median age at diagnosis, y (range)	60 (24-83)	66 (36-89)
Sex (%)		
Male	66 (46)	25 (55)
Female	77 (54)	20 (45)
Presentation at diagnosis (%)		
Primary lesion*	111 (78)	43 (96)
Recurrence	32 (22)	2 (4)
Tumor size (mm)		
Median	160	150
Mean	165	157
Range	10-500	30-340
Location (%)		
Upper limbs	10 (7)	3 (7)
Lower limbs*	57 (40)	29 (64)
Retroperitoneum*	50 (35)	3 (7)
Paratesticular area	6 (4)	2 (4)
Pelvis	4 (3)	1 (2)
Others	16 (11)	7 (16)
Histologic subtype (%)		
Lipoma-like*	59 (41)	25 (56)
Sclerosing	23 (16)	4 (9)
Inflammatory	2 (1)	2 (4)
Spindle cell	0	2 (4)
Dedifferentiated*	59 (41)	12 (27)
Grade (%)		
1	88 (62)	31 (69)
2	37 (26)	7 (16)
3	14 (10)	4 (9)
Unknown	4 (3)	3 (7)

\* $P < 0.05$  (statistically significant difference).




**Fig. 2.** Status of *P16INK4a*, *RB1* and *CCND1* in *MDM2+/CDK4+* and *MDM2+/CDK4-* WDLPS/DDLPS. *A*, dual-color FISH assays using *p16* (red) and chromosome-9 centromere (CEP9, green) showing balanced disomy. *C*, FISH analysis with BAC probe RP11-839E5 (*RB1*) showing balanced disomy. *E*, FISH analysis with BAC probe RP11-156B3 (*CCND1*) showing balanced disomy. *B*, *D*, *F*, qRT-PCR analysis measuring *P16INK4a*, *RB1*, and *CCND1* expression in 7 *MDM2+/CDK4-* (purple bars) and 13 *MDM2+/CDK4+* (light blue bars) WDLPS/DDLPS. Gene expression was quantified by qRT-PCR, normalized to levels of *RPLP0* mRNA and expressed as fold changes relative to s.c. normal adipose tissue.

observed in the *MDM2+/CDK4+* group and only one in the *MDM2+/CDK4-* group (31% versus 4%;  $P = 0.0116$ ). In all the cases but three, deaths related to the disease were observed in patients with retroperitoneal DDLPS.

**CDK4 is not overexpressed in *MDM2+/CDK4-* WDLPS/DDLPS.** QRT-PCR analysis showed a strong overexpression

of *CDK4* in the *MDM2+/CDK4+* cases analyzed whereas no significant overexpression was observed in the *MDM2+/CDK4-* cases (mean level compared with NSAT in *MDM2+/CDK4+* WDLPS, 16.9; mean level compared with NSAT in *MDM2+/CDK4-* WDLPS, 1.76;  $P = 0.0005$ ). Four cases of *MDM2+/CDK4-* WDLPS/DDLPS were also analyzed by





**Fig. 3.** Status of P16INK4a and CCND1 assessed by immunohistochemistry in *MDM2+/CDK4+* and *MDM2+/CDK4-* WDLPS/DDLPS. A and B, P16INK4a and CCND1 immunohistochemistry in a case of *MDM2+/CDK4+* WDLPS showing positive staining for P16INK4a (A) and CCND1 (B). C and D, P16INK4a and CCND1 immunohistochemistry in a case of *MDM2+/CDK4-* DDLPS showing positive staining for P16INK4a (C) and CCND1 (D).

immunohistochemistry for *CDK4* expression. All the four cases were negative for *CDK4*. We also analyzed the expression status of *CDK6* which encodes a protein that is also a kinase partner of *CCND1*. A trend for a higher expression of *CDK6* was observed in *MDM2+/CDK4-* WDLPS/DDLPS (mean level compared with NSAT in *MDM2+/CDK4-* WDLPS, 7.6; range, 0.7-40.6) in comparison with *MDM2+/CDK4+* WDLPS/DDLPS (mean level compared with NSAT in *MDM2+/CDK4+* WDLPS/DDLPS, 1.9; range, 0.7-4.5). However, this trend in the series was only due to a single case of *MDM2+/CDK4-* WDLPS/DDLPS showing a strong overexpression of *CDK6* (fold change 40.6). It was not statistically significant ( $P = 0.16$ ).

**The *CDKN2A* locus is neither deleted nor gained in most WDLPS/DDLPS cases, independently of the *CDK4* amplification status (Fig. 2).** Twenty-seven cases (10 *MDM2+/CDK4+*; 17 *MDM2+/CDK4-*) evaluated by FISH exhibited euploidy for chromosome 9 and *CDKN2A*. Heterozygous deletion of *CDKN2A* was found in only one case of WDLPS/DDLPS (*MDM2+/CDK4+*), and *CDKN2A* gain (3 to 5 copies) related to polysomy for chromosome 9 was observed in two cases (one *MDM2+/CDK4+*; one *MDM2+/CDK4-*).

**P16INK4a is consistently overexpressed in both *MDM2+/CDK4+* and *MDM2+/CDK4-* WDLPS/DDLPS (Figs. 2 and 3).** QRT-PCR analysis showed overexpression of *P16INK4a* in all the 20 cases analyzed (13 *MDM2+/CDK4+* cases including the case with heterozygous deletion of *CDKN2A* and 7 *MDM2+/CDK4-* cases;

Fig. 2). The level of overexpression was significantly higher in cases with amplification of *CDK4* (mean level compared with NSAT in *MDM2+/CDK4+* WDLPS, 58.85; range: 6.5-135; mean level compared with NSAT in *MDM2+/CDK4-* WDLPS, 18.7; range: 4.1-60.9;  $P = 0.0043$ ). Nineteen cases (7 *MDM2+/CDK4+* WDLPS/DDLPS and 12 *MDM2+/CDK4-* WDLPS/DDLPS) were also analyzed by immunohistochemistry for P16 protein expression. A positive labeling for P16 was observed in all the cases but three (one *MDM2+/CDK4+* WDLPS/DDLPS and two *MDM2+/CDK4-* WDLPS/DDLPS).

*P14ARF* was also overexpressed in all the cases analyzed (mean level compared with NSAT in *MDM2+/CDK4+* WDLPS, 35.8; range, 10.8-84.9; mean level compared with NSAT in *MDM2+/CDK4-* WDLPS, 12.6; range, 6.7-22.9;  $P = 0.0064$ ).

***CCND1* is neither deleted nor gained in most WDLPS/DDLPS cases and is frequently overexpressed in WDLPS/DDLPS independently of the *CDK4* amplification status (Figs. 2 and 3).** Twenty-nine cases (12 *MDM2+/CDK4+*, 17 *MDM2+/CDK4-*) evaluated by FISH exhibited disomy for *CCND1*. Gain (3 to 5 copies) of *CCND1* was found in only one case of WDLPS/DDLPS (*MDM2+/CDK4-*). QRT-PCR analysis showed overexpression of *CCND1* in 14 of 20 cases analyzed, independently of the *CDK4* status (9 *MDM2+/CDK4+*, 6 *MDM2+/CDK4-*; 69% versus 86%;  $P = 0.42$ ; mean level compared with NSAT in *MDM2+/CDK4+* WDLPS/DDLPS, 7.3; range, 0.9-16.6; mean level compared with NSAT in *MDM2+/CDK4-* WDLPS/DDLPS, 4.9; range, 1.7-8.9;

$P = 0.13$ ). A reduced expression of *CCND1* was found in one case of *MDM2+/CDK4+* WDLPS/DDLPS (fold change compared with NSAT, 0.33). Nineteen cases (7 *MDM2+/CDK4+* WDLPS/DDLPS, 12 *MDM2+/CDK4-* WDLPS/DDLPS) were also analyzed by immunohistochemistry for *CCND1* protein expression. A positive labeling was observed in 15 cases, a negative labeling in 3 cases (3 *MDM2+/CDK4-* WDLPS), and the result was not interpretable in 1 case.

***RB1* gene is neither deleted nor gained in most WDLPS/DDLPS cases and frequently shows a reduced expression independently of the *CDK4* amplification status (Fig. 2).** Twenty-nine cases (12 *MDM2+/CDK4+*, 17 *MDM2+/CDK4-*) evaluated by FISH exhibited disomy for *RB1*. Gain (3 to 5 copies) of *RB1* was found in only one case of WDLPS/DDLPS (*MDM2+/CDK4-*). QRT-PCR analysis showed a reduced expression ( $\geq 50\%$ ) of *RB1* in 8 of the 20 cases analyzed independently of the *CDK4* status (4 *MDM2+/CDK4+*, 4 *MDM2+/CDK4-*; 57% versus 31%;  $P = 0.25$ ; mean level compared with NSAT in *MDM2+/CDK4+* WDLPS/DDLPS, 0.32; range, 0.3-2.9; mean level compared with NSAT in *MDM2+/CDK4-* WDLPS/DDLPS, 0.36; range, 0.18-1.7). In all the cases but one, reduced expression of *RB1* and overexpression of *CCND1* were mutually exclusive.

**Detection of 1q21-23 amplification in *MDM2+/CDK4-* WDLPS/DDLPS.** Three cases of *MDM2+/CDK4-* WDLPS/DDLPS were analyzed by array-CGH in order to detect specific genomic imbalances. The results are summarized in Table 2. Besides the 12q14-15 region, the sole recurrently amplified region was 1q21-23 in the three cases. No aberration of the *CDKN2A*, *CCND1* and *RB1* loci were detected in these three cases in accordance with the FISH results.

## Discussion

We recently reported that *HMGA2* and *MDM2* were always coamplified in WDLPS/DDLPS whereas *CDK4* belonged to a distinct inconsistent amplicon (6). These results suggested that the amplification of *CDK4* might not be as indispensable as the amplification of *HMGA2* and *MDM2* for WDLPS/DDLPS tumorigenesis.

In the present study, we found that WDLPS/DDLPS lacking *CDK4* amplification were significantly associated with peculiar clinicopathologic features. Indeed, most of these lesions were low-grade lipoma-like WDLPS located in the limbs. Their rates of local recurrence and lethality were lower than those of *MDM2+/CDK4+* lesions that were significantly more often retroperitoneal. Although a correlation between amplification/overexpression of *CDK4* and a bad prognosis has been described in several tumor types (10-15), our results may also reflect the fact that free surgical margins are more easily obtained for lesions of the extremities than for retroperitoneal ones. Indeed, the disease-related mortality, typically associated with complications of multiple local recurrences, is higher for patients with retroperitoneal tumors than for those with peripheral tumors. Therefore, because our data are retrospective, the independent prognostic value of the *CDK4* amplification remains to be confirmed in a prospective way.

The alternative occurrence of *CDK4*, *p16INK4a*, *CCND1*, or *RB1* aberrations has been described in several tumor types (16-24). Indeed, the losses of *p16INK4a* or *RB1* functions as well as overexpression of *CCND1* represent alternative mechanisms for *CDK4* amplification (25). In our study, however, we

**Table 2.** Array-CGH analysis of three cases of *MDM2+/CDK4-* WDLPS/DDLPS

	Aberration	Chromosomal location	Size (Mb)
Case 1	+ 1q23.2-1q23.3	157.467-160.713	3.2
	+ 2q14.3-2q21.1	127.839-131.237	3.4
	+ 2q24.1	155.745-159.178	3.4
	+ 8p11.1-8p12	30.172-43.787	13.6
	+ 12q13.2-12q13.3	52.098-53.203	1.1
	+ 12q15-12q21.31	67.347-79.526	12.2
	+ 12q21-31	78.745-80.543	1.8
	+ 1q21.1-1q21.3	144.480-153.108	8.6
	+ 1q23.2-1q25.1	157.578-173.190	15.6
	+ 2p11.1-2p11.2	88.679-91.303	2.6
Case 2	+ 7q11.21	57.980-62.015	4
	- 9q12-13	67.862-70.514	2.6
	+ 12q13.13-12q13.2	52.698-53.730	1
	+ 12q15	67.347-67.926	0.6
	+ 12q21.2-12q21.31	74.117-79.607	5.5
	+ 12q21.31	79.699-83.470	3.8
	+ 12q21.31-12q21.32	82.333-87.375	5
	+ 1p36	16.581-16.880	0.3
	+ 1p21	101.859-106.510	4.7
	+ 1q21-1q31	145.676-197.012	51.5
Case 3	- 3p21	50.188-50.533	0.4
	+ 5q21-5q31	98.438-131.910	33
	+ 12q14-12q23	63.785-102.490	39
	+ 22q11.2	19.570-20.213	0.7

did not find any significant aberrations of the *CDKN2A*, *CCND1*, or *RB1* genes that were confined to *MDM2+/CDK4-* WDLPS/DDLPS only. The *CDKN2A* gene encodes two tumor suppressor proteins, *p16INK4a* and *p14ARF*, by a mechanism of alternative splicing of the first exon. By using FISH, we did not find deletions of *CDKN2A*. We observed a strong overexpression of *P16INK4a* and *P14ARF* in both *MDM2+/CDK4+* and *MDM2+/CDK4-* WDLPS/DDLPS. Such an overexpression of tumor suppressor genes in malignant tumor cells is very intriguing. In this regard, it is interesting to note that *P16INK4a* overexpression was significantly higher in *MDM2+/CDK4+* WDLPS/DDLPS than in *MDM2+/CDK4-* WDLPS/DDLPS. *P16INK4a* overexpression has been reported in several tumor types such as gliomas (26), myxoid liposarcomas (27), thyroid carcinomas (28), and cervical carcinomas (29). *P16INK4a* overexpression might be a secondary event to *RB1* inactivation, because *RB1* repressed *P16INK4a* at the transcriptional level (30, 31). In our series, *RB1* expression was significantly reduced in 40% of the cases, independently of the *CDK4* status. This suggests that in at least a subset of WDLPS/DDLPS, inactivation of *RB1* and *CDK4* overexpression may act as synergic or additional events to enhance the  $G_1$ -S transition and that the expressions of *CDKN2A/P16* and *RB* are not always inversely related (32). An alternative explanation for *P16INK4a* overexpression in WDLPS/DDLPS might be related to the role of *HMGA2*. Although there are several lines of evidence indicating that *HMGA2* should be considered an authentic oncogene (33), recent findings have shown that *HMGA2* may also exhibit antioncogenic properties by playing a role in cellular senescence (34). Interestingly, Narita et al. have shown that high levels of *HMGA2* expression induce *P16INK4a* expression in human diploid fibroblast and that the expression of *MDM2* or *CDK4* allowed such cells to bypass *HMGA2*-induced proliferation arrest (34). Therefore,



the high level of *P16INK4a* in WDLPS/DDLPS might be related to the overexpression of *HMG2*, the antiproliferative activity of which is circumvented by the consistent amplification of *MDM2*. Data about the respective expression of *P14ARF* and *P16INK4a* in tumor cells are scarce. The strong overexpression of both *MDM2* and *P14ARF* in WDLPS/DDLPS suggests that p53 inactivation in WDLPS/DDLPS is the result of a complex regulation. Indeed, the physiologic function of p14ARF protein is to bind to the MDM2 protein and to inhibit its ubiquitin ligase activity, increasing the levels of the p53 protein (35). The expression of *p14ARF* is directly activated by E2F1 (36). Therefore, the overexpression of *p14ARF* in WDLPS/DDLPS may result from several oncogenic events that could deregulate the E2F1 activity, such as RB1 inactivation and CDK4 or CCND1 overexpression. We have shown that *CCND1* is consistently overexpressed in WDLPS/DDLPS whatever the *CDK4* status. Besides forming active complexes with CDK4 or CDK6 that promote cell cycle progression, *CCND1* also functions as a transcriptional modulator by regulating the activity of several transcription factors and histone deacetylase (HDAC3; ref. 37). This latter activity that may play an important role in tumorigenesis is independent of CDK4. Although up-regulation of *CCND1* protein in cancer frequently results from translational and/or posttranslational mechanisms (38), *CCND1* mRNA is also overexpressed in several tumor types including nonadipose soft-tissue tumors (39, 40).

In order to obtain a global overview of genomic imbalances in *MDM2+/CDK4-* WDLPS/DDLPS, we analyzed three of these cases by array-CGH. As previously reported in *MDM2+/CDK4+* WDLPS/DDLPS, two to five regions were coamplified with 12q14-15 in all the cases (41, 42). The sole recurrently region to be coamplified with 12q14-15 in *MDM2+/CDK4-* cases was 1q21-23. This aberration cannot be considered as specific to *MDM2+/CDK4-* WDLPS/DDLPS because it has also been de-

scribed in *MDM2+/CDK4+* WDLPS/DDLPS (41, 42). Although several genes located at 1q21-q23, including *ATF6*, *DUSP12*, *COAS1*, *COAS2*, *COAS3*, *PRUNE*, and *FASLG*, have previously been reported to be amplified in supernumerary ring and giant markers in WDLPS/DDLPS as well as in other sarcomas (42-45), the targets of the 1q21-23 amplicon, which are supposed to play an effective role in WDLPS/DDLPS tumorigenesis, are still unknown.

In summary, we have shown here that *MDM2+/CDK4-* WDLPS/DDLPS represent a distinct clinical subgroup with favorable prognostic features. Although *CDKN2A* deletion is a frequent event in human cancers, our results show that this aberration is not involved in the pathogenesis of WDLPS/DDLPS even in those lacking *CDK4* amplification. Moreover, we have shown a complex pattern of expression for *CCND1*, *P16INK4a*, *P14ARF*, and *RB1* that is not dependent on the *CDK4* status. These results underscore the complex coordinated regulation of the RB and p53 growth-control pathways in WDLPS/DDLPS. The knowledge of the way by which WDLPS/DDLPS cells regulate the mitogenic and antimitogenic signaling pathways during the cell cycle is of crucial importance for the design of new therapeutic strategies. Our results represent an important basis for further investigations with the aim of determining how the activities of the actors of the *CCND1/CDK4/P16INK4a/RB1/E2F* pathway are coordinated in WDLPS/DDLPS.

### Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

### Acknowledgments

We thank Dr. Marion Marty for her assistance with the immunohistochemistry experiments and Mrs. Stephanie Bonnafous for expert technical assistance.

### References

- Ortega S, Malumbres M, Barbacid M. Cyclin D-dependent kinases, INK4 inhibitors and cancer. *Biochim Biophys Acta* 2002;1602:73-87.
- Serrano M, Lee H, Chin L, Cordon-Cardo C, Beach D, DePinho RA. Role of the INK4a locus in tumor suppression and cell mortality. *Cell* 1996; 85:27-37.
- Lee YM, Sicinski P. Targeting cyclins and cyclin-dependent kinases in cancer: lessons from mice, hopes for therapeutic applications in human. *Cell Cycle* 2006;5:2110-4.
- Fletcher C, Unni K, Mertens F. World Health Classification of tumors. Pathology and Genetics of Tumours of Soft Tissue and Bone. Lyon: IARC Press; 2002.
- Pedeutour F, Italiano A. Adipose tumors. In: Schwab M, editor. Encyclopedia of Cancer. 2nd ed Berlin: Springer-Verlag; 2008.
- Italiano A, Bianchini L, Keslair F, et al. HMG2 is the partner of MDM2 in well-differentiated and dedifferentiated liposarcomas whereas CDK4 belongs to a distinct inconsistent amplicon. *Int J Cancer* 2008;122:2233-41.
- Pérez de Castro I, de Cárcer G, Montoya G, Malumbres M. Emerging cancer therapeutic opportunities by inhibiting mitotic kinases. *Curr Opin Pharmacol* 2008;8:375-83.
- Sirvent N, Coindre JM, Maire G, et al. Detection of MDM2-4 amplification by fluorescence *in situ* hybridization in 200 paraffin-embedded tumor samples: utility in diagnosing adipocytic lesions and comparison with immunohistochemistry and real-time PCR. *Am J Surg Pathol* 2007;31: 1476-89.
- Italiano A, Attias R, Aurias A, et al. Molecular cytogenetic characterization of a metastatic lung sarcomatoid carcinoma: 9p23 neocentromere and 9p23-24 amplification including *JAK2* and *JMJD2C*. *Cancer Genet Cytogenet* 2006;167: 122-30.
- Volm M, Koomägi R, Stammler G, Rittgen W, Zintl F, Sauerbrey A. Prognostic implications of cyclins (D1, E, A), cyclin-dependent kinases (CDK2, CDK4) and tumor-suppressor genes (pRB, p16INK4A) in childhood acute lymphoblastic leukemia. *Int J Cancer* 1997;74:508-12.
- Yeager T, Stadler W, Belair C, Puthenveetil J, Olopade O, Reznikoff C. Increased p16 levels correlate with pRb alterations in human urothelial cells. *Cancer Res* 1995;55:493-7.
- Dong Y, Sui L, Sugimoto K, Tai Y, Tokuda M. Cyclin D1-4 complex, a possible critical factor for cell proliferation and prognosis in laryngeal squamous cell carcinomas. *Int J Cancer* 2001; 95:209-15.
- Simon R, Struckmann K, Schraml P, et al. Amplification pattern of 12q13-q15 genes (*MDM2*, *CDK4*, *GLI*) in urinary bladder cancer. *Oncogene* 2002;21:2476-83.
- Zhao P, Hu YC, Talbot IC. Expressing patterns of p16 and CDK4 correlated to prognosis in colorectal carcinoma. *World J Gastroenterol* 2003;9: 2202-6.
- Ghazizadeh M, Jin E, Shimizu H, et al. Role of *cdk4*, *p16INK4*, and *Rb* expression in the prognosis of bronchioloalveolar carcinomas. *Respiration* 2005;72:68-73.
- Otterson GA, Kratzke RA, Coxon A, Kim YW, Kaye FJ. Absence of p16INK4 protein is restricted to the subset of lung cancer lines that retains wild-type RB. *Oncogene* 1994;9:3375-8.
- He J, Olson JJ, James CD. Lack of p16INK4 or retinoblastoma protein (pRb), or amplification-associated overexpression of *cdk4* is observed in distinct subsets of malignant glial tumors and cell lines. *Cancer Res* 1995;55:4833-6.
- Shapiro GI, Edwards CD, Kobzik L, et al. Reciprocal Rb inactivation and p16INK4 expression in primary lung cancers and cell lines. *Cancer Res* 1995;55:505-9.
- Yeager T, Stadler W, Belair C, Puthenveetil J, Olopade O, Reznikoff C. Increased p16 levels correlate with pRb alterations in human urothelial cells. *Cancer Res* 1995;55:493-7.
- Kratzke RA, Greatens TM, Rubins JB, et al. Rb and p16INK4a expression in resected non-small cell lung tumors. *Cancer Res* 1996;56:3415-20.
- Sakaguchi M, Fujii Y, Hirabayashi H, et al. Inversely correlated expression of p16 and Rb protein in non-small cell lung cancers: an immunohistochemical study. *Int J Cancer* 1996;65:442-5.
- Wei G, Lonardo F, Ueda T, et al. CDK4 gene amplification in osteosarcoma: reciprocal relationship with INK4A gene alterations and mapping of 12q13 amplicons. *Int J Cancer* 1999;80: 199-204.
- Koontongkaew S, Chareonkitkajorn L, Chanvitan A, Leelakriangsak M, Amornphimoltham P. Alterations of p53, pRb, cyclin D(1) and *cdk4* in human oral and pharyngeal squamous cell carcinomas. *Oral Oncol* 2000;36:334-9.
- Park HW, Song SY, Lee TJ, Jeong D, Lee TY.

- Abrogation of the p16-retinoblastoma-cyclin D1 pathway in head and neck squamous cell carcinomas. *Oncol Rep* 2007;18:267-72.
25. Ruas M, Peters G. The p16INK4a/CDKN2A/P16 tumor suppressor and its relatives. *Biochim Biophys Acta* 1998;1378:F115-77.
26. Nishikawa R, Furnari FB, Lin H, et al. Loss of P16INK4 expression is frequent in high grade gliomas. *Cancer Res* 1995;55:1941-5.
27. Olofsson A, Willén H, Göransson M, et al. Abnormal expression of cell cycle regulators in FUS-CHOP carrying liposarcomas. *Int J Oncol* 2004;25:1349-55.
28. Ferru A, Fromont G, Gibelin H, et al. The status of CDKN2A/P16  $\alpha$ (p16INK4A) and  $\beta$ (p14ARF) transcripts in thyroid tumour progression. *Br J Cancer* 2006;95:1670-7.
29. Ivanova TA, Golovina DA, Zavalishina LE, et al. Up-regulation of expression and lack of 5' CpG island hypermethylation of p16 INK4a in HPV-positive cervical carcinomas. *BMC Cancer* 2007;7:47.
30. Li Y, Nichols MA, Shay JW, Xiong Y. Transcriptional repression of the D-type cyclin-dependent kinase inhibitor p16 by the retinoblastoma susceptibility gene product pRb. *Cancer Res* 1994;54:6078-82.
31. Lukas J, Parry D, Aagaard L, et al. Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16. *Nature* 1995;375:503-6.
32. Kanoe H, Nakayama T, Murakami H, et al. Amplification of the CDK4 gene in sarcomas: tumor specificity and relationship with the RB gene mutation. *Anticancer Res* 1998;18:2317-21.
33. Fusco A, Fedele M. Roles of HMGA proteins in cancer. *Nat Rev Cancer* 2007;7:899-910.
34. Narita M, Narita M, Krizhanovsky V, et al. A novel role for high-mobility group a proteins in cellular senescence and heterochromatin formation. *Cell* 2006;126:503-14.
35. Honda R, Yasuda H. Association of p19(ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53. *EMBO J* 1999;18:22-7.
36. Bates S, Phillips AC, Clark PA, et al. p14<sup>ARF</sup> links the tumour suppressors RB and p53. *Nature* 1998;395:124-5.
37. Coqueret O. Linking cyclins to transcriptional control. *Gene* 2002;299:35-55.
38. Alao JP. The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic intervention. *Mol Cancer* 2007;6:24.
39. Maelandsmo GM, Berner JM, Flørenes VA, et al. Homozygous deletion frequency and expression levels of the CDKN2 gene in human sarcomas-relationship to amplification and mRNA levels of CDK4 and CCND1. *Br J Cancer* 1995;72:393-8.
40. Zhang J, Hu S, Schofield DE, Sorensen PH, Triche TJ. Selective usage of D-Type cyclins by Ewing's tumors and rhabdomyosarcomas. *Cancer Res* 2004;64:6026-34.
41. Pedetour F, Forus A, Coindre JM, et al. Structure of the supernumerary ring and giant rod chromosomes in adipose tissue tumors. *Genes Chromosomes Cancer* 1999;24:30-41.
42. Persson F, Olofsson A, Sjögren H, et al. Characterization of the 12q amplicons by high-resolution, oligonucleotide array CGH and expression analyses of a novel liposarcoma cell line. *Cancer Lett* 2008;260:37-47.
43. Forus A, D'Angelo A, Henriksen J, et al. Amplification and overexpression of PRUNE in human sarcomas and breast carcinomas - a possible mechanism for altering the nm23-H1 activity. *Oncogene* 2001;20:6881-90.
44. Meza-Zepeda LA, Forus A, Lygren B, et al. Positional cloning identifies a novel cyclophilin as a candidate amplified oncogene in 1q21. *Oncogene* 2002;21:2261-9.
45. Kresse SH, Berner JM, Meza-Zepeda LA, et al. Mapping and characterization of the amplicon near APOA2 in 1q23 in human sarcomas by FISH and array CGH. *Mol Cancer* 2005;4:39.